Defunct Company
Total Trials
3
As Lead Sponsor
As Collaborator
0
Total Enrollment
660
NCT04099641
An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 11, 2019
Completion: Oct 26, 2022
NCT05453825
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
Start: Aug 5, 2022
Completion: Dec 15, 2024
NCT05043402
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
Phase: Phase 3
Start: Nov 30, 2022
Completion: Aug 15, 2024